Opyl Limited

Equities

OPL

AU0000070856

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 08:01:31 17/07/2024 am IST			5-day change	1st Jan Change
0.027 ^AUD	0.00%		0.00%	-3.57%

08/07	Opyl Enters Partnership to Create Biotech Fund; Shares Up 8%	MT
06/06	Opyl Secures First TrialGen Contract with Brain Vector	MT

ShareRoot Limited announced that it has received AUD 0.81 million in funding

January 23, 2018

ShareRoot Limited (ASX:SRO) announced a private placement of 162,936,288 common shares at a price of AUD 0.005 for gross proceeds of AUD 814,681 to sophisticated and professional investors on January 23, 2018.

Latest news about Opyl Limited

Opyl Enters Partnership to Create Biotech Fund; Shares Up 8%	08/07	MT
Opyl Secures First TrialGen Contract with Brain Vector	06/06	MT
Opyl Expands TrialKey Coverage; Shares Up 38%	29/04	MT
Opyl to Divest Opin Business	23/04	MT
Opyl Receives Offer for Patient Recruitment Business	22/03	MT
Trial Screen Pty Ltd entered into a non-binding offer to acquire Opin business from Opyl Limited.	22/03	CI
Opyl Requests Trading Halt After Receiving Offer For Opin Business	20/03	MT
Opyl Chair Stepping Down in End-April	15/03	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Opyl Raises Nearly AU$900,000 from Rights Issue Shortfall Placement	09/02	MT
Opyl Grows Cash Receipts for Fiscal Q2	31/01	MT
Opyl Receives Commitments for Potential Shortfall	02/01	MT
Opyl Appoints Interim CEO	24/11	MT
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer	24/11	CI
Opyl Secures R&D Tax Rebate for Fiscal Year 2023	22/23/22	MT
Opyl Limited Announces Appointment of Antanas Guoga as Director, Effective from September 4, 2023	05/23/05	CI
Opyl Limited Announces Board Update	04/23/04	CI
Opyl Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Opyl Limited Launches TrialKey MVP	24/23/24	CI
Opyl Limited Announces Senior Leadership Changes	05/23/05	CI
Opyl Limited Announces Resignation of Michelle Gallaher as CEO	05/23/05	CI
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor	02/23/02	CI
Opyl Completes Issuance of Shortfall Shares	04/23/04	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2022	27/23/27	CI
Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023	27/23/27	CI

Chart Opyl Limited

Duration

Period

More charts

Company Profile

Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.

Sector

Advanced Medical Equipment & Technology

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
OPYL LIMITED	-3.57%	31L
VEEVA SYSTEMS INC.	-5.50%	2.94TCr
PRO MEDICUS LIMITED	+37.09%	945.23Cr
SECTRA AB	+32.25%	434.17Cr
EVOLENT HEALTH, INC.	-36.88%	239.1Cr
VERADIGM INC.	-6.48%	165.62Cr
OMNICELL, INC.	-23.84%	131.62Cr
LUNIT INC.	-42.92%	98Cr
SIMULATIONS PLUS, INC.	-3.96%	86Cr
B-SOFT CO.,LTD.	-50.69%	69Cr

Medical Software & Technology Services